Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS In this interview with Oncology Data Advisor, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center, discusses the significance of Magtrace™, a liquid tracer which has recently become a game changer in guiding surgical decisions for patients with breast cancer.  
World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.  
Tackling Violence and Stigmatization to Decrease Cancer Disparities for Transgender Patients With Ash Alpert, MD, MFA
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Tackling Violence and Stigmatization to Decrease Disparities for Transgender Patients: Ash Alpert At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Dr. Ash Alpert, a postdoctoral fellow in health services research at Brown University, presented two posters regarding the associations between violence and cancer risk factors for transgender and cisgender people. In this follow-up interview with Oncology Data Advisor, Dr. Alpert delves further into the implications of these two studies' results and shares how their ongoing research in this field seeks to improve the care of transgender people in the health care setting.  
Understanding Antibody-Drug Conjugates and Their Use in the Treatment of Breast Cancer With Ian Krop, MD, PhD
Elizabeth Heller, PhD
Expert Analysis
Oncology Data Advisor™ · Patritumab Deruxtecan for HER3-Expressing Metastatic Breast Cancer: Ian Krop, MD, PhD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Ian Krop, Director of the Yale Cancer Center Clinical Trials Office, sat down with Oncology Data Advisor to discuss his research and the data he presented regarding the HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) for treatment of metastatic breast cancer.This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMED.  
Changing the Standard of Care for Pediatric Neuroblastoma With Wendy London, PhD
Elizabeth Heller, PhD
Expert Analysis
Oncology Data Advisor™ · Neuroblastoma Risk Stratification and Research: Wendy London, PhD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Wendy London, Associate Professor of Pediatrics at Harvard Medical School, sat down with Oncology Data Advisor to share her research regarding risk stratification, reduction of therapy, and survival outcomes for pediatric patients with neuroblastoma. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.
Exploring Treatment Outcomes for Lobular Breast Cancer With Jason Mouabbi, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Lobular Breast Cancer Histology and Research: Jason Mouabbi, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Jason Mouabbi of MD Anderson Cancer Center presented a poster focused on survival outcomes of patients with invasive lobular carcinoma treated with endocrine therapy plus a CDK4/6 inhibitor, mammalian target of rapamycin (mTOR) inhibitor, or a PI3K inhibitor, in comparison to those with metastatic hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative invasive ductal carcinoma. Afterwards, he sat down with Oncology Data Advisor to explain the implication of the study's results and the need for additional research in the field of lobular breast cancer to improve patient outcomes.  This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.  
Sharing the Breast Cancer Journey From Diagnosis to Survivorship With Megan-Claire Chase
Keira Smith
Expert Analysis
Oncology Data Advisor™ · A Patient's Perspective on Breast Cancer and Advocacy: Megan - Claire Chase At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Megan-Claire Chase, breast cancer survivor and Breast Cancer Program Director at SHARE Cancer Support, sat down with Oncology Data Advisor to talk about her diagnosis, treatment, and survivorship journey, as well as her advocacy work to empower people living with cancer. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 
Understanding the Research on Novel Treatments and Nutritional Interventions for Multiple Myeloma With Urvi Shah, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Best of Multiple Myeloma Research at ASCO: Urvi Shah, MD During the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Urvi Shah from Memorial Sloan Kettering Cancer Center sat down with Oncology Data Advisor to share her perspectives on the exciting research that was presented in the poster discussion session she chaired on novel therapies for multiple myeloma. In addition, Dr. Shah explains more about her work to impact patients' quality of life and outcomes through nutritional interventions. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. 
Exploring the Impact of Cemiplimab and Pembrolizumab in Cutaneous Squamous Cell Carcinoma With Shaheer Khan, DO
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Exploring the Impact of Cemiplimab and Pembrolizumab in Cutaneous Squamous Cell Carcinoma In honor of Melanoma Awareness Month, Oncology Data Advisor spoke with Dr. Shaheer Khan, an Assistant Professor of Medicine at Columbia University Irving Medical Center. Dr. Khan shares the promising results of two recent ...
Oncology Nursing Month With Maria Badillo and Sherry Adkins: Nursing Considerations for CAR T-Cell Therapy
Keira Smith
Expert Analysis
In honor of Oncology Nursing Month in May, Oncology Data Advisor is celebrating the stories of these essential members of the cancer care team. For this interview, editorial board member Maria Badillo, MSN, RN, OCN®, CCRP, speaks with Sherry Adkins, MSN, ANP-C, Advanced Practice Provider Supervisor at MD Anderson Cancer Center, about her groundbreaking research in the development of chimeric antigen (CAR) T-cell therapies and the critical role that oncology nurses play in caring for patients receiving this novel therapeutic strategy.  
Taking a Nuanced Approach to Testicular Cancer Management With Sam Kaffenberger, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Taking a Nuanced Approach to Testicular Cancer Management With Sam Kaffenberger, MD For this interview in honor of Testicular Cancer Awareness Month, Dr. Sam Kaffenberger, an Assistant Professor of Urology at the University of Michigan Health System, explains the importance of taking a nuanced approach to the m...
Can Digital Health Tools Improve Quality of Life in Multiple Myeloma? Insights from Neha Korde, MD, and Rahul Banerjee, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor™ · Can Digital Health Tools Improve Quality of Life in Multiple Myeloma? In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Neha Ko...
Exploring Recent Advances in Testicular Cancer Surgery and Access to Care With Andrew Winer, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Exploring Recent Advances in Testicular Cancer Surgery and Access to Care This interview in honor of Testicular Cancer Awareness Month features Dr. Andrew Winer, Chief of Urology at Kings County Hospital in New York. Dr. Winer discusses the ongoing research regarding new approaches for testicular cancer surgery...
Personalizing the Approach to Testicular Cancer Management With Aditya Bagrodia, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Personalizing the Approach to Testicular Cancer Management With Aditya Bagrodia, MD, FACS This interview in honor of Testicular Cancer Awareness Month features Dr. Aditya Bagrodia, an Associate Professor of Urology at the University of California, San Diego. Dr. Bagrodia explains the factors that should be cons...
Considering Venous Thromboembolism Risk Factors and Prophylaxis in Multiple Myeloma With Rajshekhar Chakraborty, MD, and Rahul Banerjee, MD
Keira Smith
Special Episode
Oncology Data Advisor™ · Considering VTE Risk Factors and Prophylaxis in Myeloma: Rajshekhar Chakraborty and Rahul Banerjee In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial B...
Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Food for Thought From Urvi Shah, MD, and Rahul Banerjee, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Urvi Shah and Rahul Banerjee In honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah...
The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD Recently, the FDA granted approval to tebentafusp for the treatment of patients with human leukocyte antigen (HLA)-A*02:01–positive unresectable or metastatic uveal melanoma, marking the first agent to be approved for this r...
Advocating for Patients During Multiple Myeloma Clinical Trial Design and Post-Protocol: Manni Mohyuddin, MBBS, and Rahul Banerjee, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Advocating for Patients in Multiple Myeloma Clinical Trials: Manni Mohyuddin and Rahul Banerjee In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial boar...
The Roles of Etiology and Biopsy in Hepatocellular Carcinoma With Augusto Villanueva, MD, PhD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Roles of Etiology and Biopsy in Hepatocellular Carcinoma With Augusto Villanueva, MD, PhD At the recent American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, Dr. Augusto Villanueva, an Associate Professor of Medicine at Mount Sinai Hospital, discussed the role of the four main etiologies of hepatocellular carcinoma (HCC) in the response that patients may experience to treatment with immune checkpoint inhibitors. In this interview, Dr. Villanueva delves further into the question of whether etiology should play a part in immune-based treatment selection, as well as the role of liquid biopsy for patients newly diagnosed with HCC.  
Rare Disease Day With Amy DeZern, MD, MHS: Making Progress in Myelodysplastic Syndromes
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Rare Disease Day With Amy DeZern, MD, MHS: Making Progress in Myelodysplastic Syndromes In honor of Rare Disease Day on February 28, Oncology Data Advisor spoke with Amy DeZern, MD, MHS, Director of the Bone Marrow Failure and Myelodysplastic Syndromes (MDS) Program at Johns Hopkins Medicine and member of the Aplastic Anemia and MDS International Foundation (AAMDSIF) medical advisory board. In this interview, Dr. DeZern explains the challenges of treating such a rare disease and shares some of recent promising updates in novel treatments for patients with MDS.  

Copyright © 2022 Oncology Data Advisor. All rights reserved.